Comparative efficacy of switching to natalizumab in active multiple sclerosis

Author
Spelman, T; Kalincik, T; Zhang, A; Pellegrini, F; Wiendl, H; Kappos, L; Tsvetkova, L; Belachew, S; Hyde, R; Verheul, F; ...Date
2015-04-01Source Title
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGYPublisher
WILEYAffiliation
Melbourne Medical SchoolRadiology
Medicine (RMH)
Surgery (St Vincent's)
Metadata
Show full item recordDocument Type
Journal ArticleCitations
Spelman, T; Kalincik, T; Zhang, A; Pellegrini, F; Wiendl, H; Kappos, L; Tsvetkova, L; Belachew, S; Hyde, R; Verheul, F; Grand-Maison, F; Izquierdo, G; Grammond, P; Duquette, P; Lugaresi, A; Lechner-Scott, J; Oreja-Guevara, C; Hupperts, R; Petersen, T; Barnett, M; Trojano, M; Butzkueven, H, Comparative efficacy of switching to natalizumab in active multiple sclerosis, ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2015, 2 (4), pp. 373 - 387Access Status
Open AccessDOI
10.1002/acn3.180Open Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402083NHMRC Grant code
NHMRC/1071124Abstract
OBJECTIVE: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between glatiramer acetate (GA) and interferon-beta (IFNβ) after an on-treatment relapse on IFNβ or GA using propensity score matched real-world datasets. METHODS: Patients included were registered in MSBase or the TYSABRI Observational Program (TOP), had relapsed on IFNβ or GA within 12 months prior to switching to another therapy, and had initiated natalizumab or IFNβ/GA treatment ≤6 months after discontinuing prior therapy. Covariates were balanced across post switch treatment groups by propensity score matching at treatment initiation. Relapse, persistence, and disability measures were compared between matched treatment arms in the total population (n = 869/group) and in subgroups defined by prior treatment history (IFNβ only [n = 578/group], GA only [n = 165/group], or both IFNβ and GA [n = 176/group]). RESULTS: Compared to switching between IFNβ and GA, switching to natalizumab reduced annualized relapse rate in year one by 65-75%, the risk of first relapse by 53-82% (mean follow-up 1.7-2.2 years) and treatment discontinuation events by 48-65% (all P ≤ 0.001). In the total population, switching to natalizumab reduced the risk of confirmed disability progression by 26% (P = 0.036) and decreased the total disability burden by 1.54 EDSS-years (P < 0.0001) over the first 24 months post switch. INTERPRETATION: Using large, real-world, propensity-matched datasets we demonstrate that after a relapse on IFNβ or GA, switching to natalizumab (rather than between IFNβ and GA) led to superior outcomes for patients in all measures assessed. Results were consistent regardless of the prior treatment identity.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
